Skip to content

Cyproheptadin plus Risperidon in treatment of children with Autistic Disorder: a double blind, placebo controlled study

Cyproheptadin plus Risperidon in treatment of children with Autistic Disorder: a double blind, placebo controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201101105280N3
Enrollment
30
Registered
2011-02-21
Start date
2008-04-08
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autistic Disorder. Childhood autism

Interventions

Intervention 1: Risperidone was started with 0.5 mg per day and incresed to 1 mg after 4 days. Dose was titrated based on clinicain's judgment and level of adverse events to maximum 2 mg per day. cy
Treatment - Drugs
Risperidone was started with 0.5 mg per day and incresed to 1 mg after 4 days. Dose was titrated based on clinicain's judgment and level of adverse events to maximum 2 mg per day. cyproheptadin was
Risperidone was started with 0.5 mg per day and incresed to 1 mg after 4 days. Dose was titrated based on clinicain's judgment and level of adverse events to maximum 2 mg per day. in this group plac

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 11 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were: children aged 3 to 11 with autistic disorder (diagnoses made by the child and adolescent psychiatrist), willingness to participate in the study. Exclusion criteria included: presence of a medical disease and taking any psychiatric drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Autistic Disorder. Timepoint: base line,weeks 4,8. Method of measurement: Childhood Autism Rating Scale(CARS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Moharari

Ibn-e-Sina Hospital, Mashhad University of Medical Sciences

mohararif1@mums.ac.ir+98 71 12721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026